North Dakota State University (NDSU) has spun out US-based oncological therapy developer Oncothira under a licence from NDSU Research Foundation, the university’s tech transfer office.
NDSU will charge Oncothira on certain development milestones and will also collect royalties on any eventual drug sales.
Founded in July 2018, Oncothira is working on a drug that tackles cancer by exploiting an enzyme prevalent in cancerous tumours called cyclooxygenase (Cox-2) to assist the production of the cancer-fighting compound 8-HOA.
Unlike Cox-2 inhibitors currently…
